Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 02 May 2017, Paris - France

Session Details

Poster Session 2: Chronic heart failure
Sun 30 Apr 08:30 - 18:00 Miscellaneous Poster Session Poster Area -

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P949Reliability of biomarkers (Nt-proBNP, Gal-3, NGAL, hsTnT, AVP, ST-2, MDA) in patients with HFrEF, HFpEF, diabetic nephropathy and arterial hypertensionDjawid HASHEMI (Berlin, Germany)
08:30P950Altered intestinal microflora in the progression of chronic heart failureBakhodir NARZIEV (Tashkent, Uzbekistan)
08:30P952Asymptomatic left ventricular dysfunction, coronariography and significant coronary artery diseaseDaniel Jorge NASCIMENTO MATOS (Lisbon, Portugal)
08:30P953The role of galectin-3 in heart failureFederica RICUPATI (Partinico, Italy)
08:30P954Practical confirmation of the predictive accuracy of a 400 ng/L NTproBNP threshold for heart failureAbdallah AL-MOHAMMAD (Barnsley, United Kingdom)
08:30P955Multi-layer longitudinal strain for noninvasive diagnosis of coronary allograft vasculopathy in heart transplant recipients: a comparative study ultrasound versus angiography.Nicolas BONNET (Paris, France)
08:30P956Feseability and safety of right and left heart catheterization via an antecubital fossa vein and the radial artery in patients with heart failure: a single centre retrospective cohort study.Domenico D'AMARIO (Rome, Italy)
08:30P957The incremental shuttle walk test for the evaluation of people at risk of developing heart Failure: a HOMAGE sub-study.Beatrice MARIOTTONI (Cortona, Italy)
08:30P958Echocardiographic diagnostic criteria for heart failure with preserved ejection fraction: does one-size fits all?Bernardo NEVES (Lisboa, Portugal)
08:30P959Nurse-led cardiovascular disease management program impact of 30-day readmission in patients with heart failureRaed ODEH (Riyadh, Saudi Arabia)
08:30P960Ranolazine alone or as an add-on to amiodarone for both prevention and cardioversion of atrial fibrillation in patients with or without chronic heart failure: a metaanalysis of the literatureRenato DE VECCHIS (Naples, Italy)
08:30P961Guideline-led prescribing among heart failure patients in the long-term care settingSeif EL HADIDI (Cork, Ireland)
08:30P962ExtraHF survey. The european survey on implementation of exercise training in heart failure patients: regional differences in structure and long term organisationAlessandro VERDE (Piacenza, Italy)
08:30P963Treatment patterns in newly diagnosed patients with heart failure managed in the primary care and cardiology settings in FranceSara BRUCE WIRTA (Basel, Sweden)
08:30P964Psychometric evaluation and health care provider feedback on a symptom tracker for use by patients with heart failureEldrin LEWIS (Boston, United States of America)
08:30P965Identifying potentially inappropriate medicines use among heart failure patients in long term care using a disease-specific toolSeif EL HADIDI (Cork, Ireland)
08:30P966OBLIC: a nationwide French prospective cohort of heart failure ambulatory patients managed in private practiceFrederic MOUQUET (Lille, France)
08:30P967Guidelines-recommended medications for heart failure in eight post-soviet countries: insights from the optimize heart failure care programYury LOPATIN (Volgograd, Russian Federation)
08:30P968Rationale and design of ARIADNE. assessment of real life care describing european heart failure managementUwe ZEYMER (Ludwigshafen, Germany)
08:30P969The role of body mass index on a n-terminal pro brain natriuretic peptide-guided versus a symptom-guided management in heart failure patients with reduced ejection fractionNick MARCKS (Maria Hoop, Netherlands)
08:30P970Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT 
08:30P971A state-wide approach to multidisciplinary care: heart failure evaluation and reporting of outcomes (HERO)Annabel HICKEY (Chermside, Australia)
08:30P972Pharmacological management of heart failure and device therapy in a british district general hospitalAmrit CHOWDHARY (Bury, United Kingdom)
08:30P973Effect of carvedilol on metoprolol succinate on mortality in heart failure with reduced ejection fractionTarek AJAM (Saint Louis, United States of America)
08:30P974Impact of mode of delivery of disease management programmes on clinical outcomes among patients following hospitalised heart failure: a systematic review and meta-analysisIain B SQUIRE (Leicester, United Kingdom)
08:30P975Effectiveness of the 'heartfailurematters.org' website in patients with stable HFFrans Hendrik RUTTEN (Utrecht, Netherlands)
08:30P976Impact of different therapeutic targets on the prognosis of heart failure patients include in a cardiac rehabilitation programLamia KESRI-TARTIERE (Hyeres, France)
08:30P977Utilization and outcomes following initiation of sacubitril/valsartan in a newly established heart failure disease management programBassam ATALLAH (Abu Dhabi, United Arab Emirates)
08:30P978Do we treat heart failure differently according to the ejection fraction?Juan Ramon BERAMENDI CALERO (Donostia-San Sebastian, Spain)
08:30P979Zero admissions for heart failureJuan Luis BONILLA PALOMAS (Cordoba, Spain)
08:30P980The long term protective role of mediterranean diet in first diagnosed acute coronary syndrome patients with heart failure with preserved ejection fraction; results from hellenic heart failure study.Christina CHRYSOHOOU (Athens, Greece)
08:30P981Ivabradine use in patients with HFrEF in the heart failure multidisciplinary program (PIC) in a private hospital: first registration and 3-years follow up, Central American (CA) region.Mario SPERANZA (San Jose, Costa Rica)
08:30P982The role of the crossover of the using the ranolazine and trimetazidine in dynamics of reduced left ventricular function in patients after anterior or lateral myocardial infarction without myocardial Jafar RAMAZANOV (Baku, Azerbaijan)
08:30P983Evaluation of an integrated group education program on quality of life for family members of patients living with heart failure 
08:30P985Impact of early tolvaptan treatment for very elderly patients with heart failure and chronic kidney diseaseKei YOSHIOKA (Moriguchi, Japan)
08:30P986Single centre audit of Right Heart study in patients with decompensated heart failure. 
08:30P987Effect of ivabradine in the vulnerable phase: results from de optimize Colombia projectClara Ines SALDARRIAGA (Medellin, Colombia)
08:30P988Heart failure: what impact does age have on betablockage and renin-angiotensin inhibition?Maria Luisa MALVAR (Vila Nova De Famalicao, Portugal)
08:30P989Tolerability and short-term outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) use in a Singaporean cohortNatalie KOH (Singapore, Singapore)
08:30P990Vasopressin receptor antagonist shortens the lengh of stay and reduces the risk of worsening renal function in hospitalized chronic heart failure patient with hyponatremia : a prospective cohort studyRarsari Soerarso PRATIKTO (Jakarta, Indonesia)
08:30P991Ivabradine reduces myocardial hibernation in patients with acute coronary syndromeLesia KOPCHAK (Village Skhidnytsia, Ukraine)
08:30P992Furosemide doses and long-term mortality after discharge from heart failure episodeJerome COSTA (Reims, France)
08:30P993Long-term sacubitril/valsartan therapy is associated with decrease of arterial elastance in stable patients with heart failure with reduced ejection fractionSvetlana VILLEVALDE (Moscow, Russian Federation)
08:30P994How improve quality of medication management in cardiology? Benefit of clinical pharmacist assistance in cardiology units. 
08:30P995Is diuretic resistance a lost battle?Rocio EIROS (Pamplona, Spain)
08:30P996IVC analysis - a reproducible and clinically relevant metric which deserves greater prominence in heart failure managementMatthew BARRETT (Dublin, Ireland)
08:30P997Un-suggested prescriptions of non-cardio-selective beta-blockers for heart failure in patients with concurrent chronic obstructive pulmonary disease: a danish nationwide retrospective cohort study.Maurizio SESSA (Napoli, Italy)
08:30P998Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysisDarryl MCGILL (Garran, Australia)
08:30P999Effect of short daily versus conventional dialysis on cardiac structure and function in patients with diuretic-resistant congestive heart failure.Katerina NAKA (Ioannina, Greece)
08:30P1000Determinants and prognostic value of peak oxygen uptake in the current era of heart failure disease modifying therapyJavier ROIBAL-PRAVIO (Puerto De Santa Cruz (Oleiros), Spain)
08:30P1001Pulsatile hemodynamics in heart failure with reduced ejection fraction - determinants and prognostic valueThomas WEBER (Wels, Austria)
08:30P1002Mathematical prediction of unfavorable course of chronic heart failureZulfya RASULOVA (Tashkent, Uzbekistan)
08:30P1003A white-coat effect for heart rate in heart failure? Characteristics and prognostic implications in idiopathic dilated cardiomyopathyArnaud BISSON (Saint Cyr Sur Loire, France)
08:30P1004Impact of tricuspid regurgitation on survival in patients with chronic heart failureKaoutar KHARBOUCHE (Casablanca, Morocco)
08:30P1005Low incidence of overt heart failure in south italy centenaries is linked with good life style: preliminary data from the ciao studyRossella MARINO (Roma, Italy)
08:30P1006The role of sodium level and in-hospital mortality in patients with acute, or acute worsening chronic heart failureMarija VAVLUKIS (Skopje, Macedonia The Former Yugoslav Republic of)
08:30P1007The beneficial effect of the management of heart failure patients with reduced ejection fraction at an outpatient clinic after hospitalization and applying guideline recommended therapy on mortalityNoemi NYOLCZAS (Budapest, Hungary)
08:30P1008Mortality rate of patients with heart failure with preserved ejection fraction on carvedilol therapy; results from the Croatian heart failure registryDomagoj MARKOVIC (Split, Croatia)
08:30P1010Heart failure and comorbidities in acute coronary syndrome prognosis; a hierarchical analysis of clinical and lifestyle factors per heart failure phenotype, from hellenic heart failure study.Christina CHRYSOHOOU (Athens, Greece)
08:30P1011Heart failure with reduced LV ejection fraction and atrial fibrillation/flutter, what predicts LV ejection fraction recovery?Siobhan LOCKWOOD (Clayton, Australia)
08:30P1012Red blood cell distribution width predicts the risk of heart failure exacerbations but not death in stable patients with chronic heart failure in a short-term observationAnna Maryla KOWALCZYS (Gdansk, Poland)
08:30P1013Heart failure in patients with acute coronary syndrome: characterization of population and impact on prognosis.Joao PAIS (Estremoz, Portugal)
08:30P1014Body composition as a risk of prolonged hospitalisations in patients with heart failure and / or respiratory distressLeslie VERDEJA VENDRELL (Puebla, Mexico)
08:30P1015Genetic predictors of acute and chronic heart failure in patients with acute acute coronary eventsValentina KOZIK (Novosibirsk, Russian Federation)
08:30P1016Polimorphism of cyp7a1 gene as marker of cardiovascular complications for hypertensive patients with 2 type diabetes and nephropathy 
08:30P1017The relation between the low triiodothyronine syndrome and plasma selenium concentration in HFrEF - Pilot study.Magdalena Maria FRACZEK-JUCHA (Krakow, Poland)
08:30P1018Significance of novel biomarkers for short-term and long-term prognosis in patients after acute heart failure decompensation 
08:30P1019Evaluation of NT-proBNP role in risk stratification of patients with heart failure in 12 and 18 months follow-upAndrea CURTI GIALDINO (Palermo, Italy)
08:30P1020Choice of an anticoagulant affects endothelial function but not long-term prognosis in patients with acute decompensated chronic heart failure 
08:30P1021Heart failure with recovered ejection fraction in malaysian cohortNoel ROSS (Petaling Jaya, Malaysia)
08:30P1022Heart failure: an open door for infections?Joana Azevedo DUARTE (Amadora, Portugal)
08:30P1023Polysomnographic respiratory parameters and left ventricular function in heart failure patients with predominant central sleep apneaKarolina SIMIONESCU (Katowice, Poland)
08:30P1024Clinical outcomes in atrial fibrillation patients with non-vitamin K antagonist oral anticoagulants and heart failureCristina GOENA VIVES (San Sebastian, Spain)
08:30P1025Sexual dysfunction: a reality in the patient with heart failureSara GONCALVES (Charneca De Caparica, Portugal)
08:30P1026Use of the minnesota living with heart failure quality of life questionnaire in kosovoArtan AHMETI (Prishtine, Kosovo Republic of)
08:30P1027Chronic systolic heart failure rehospitalization rates study from OPTIMIZE HF program: data from two centersHamayak SISAKIAN (Yerevan, Armenia)
08:30P1028Gender-specific descriptions of chronic heart failureNatalia LAREVA (Chita, Russian Federation)
08:30P1029Cognitive function in chronic heart failure: relation to clinical variablesAlina LYASHENKO (Kiev, Ukraine)
08:30P1030Microalbuminuria and glomerular filtration rate in chronic heart failure: relation to clinical variablesAlina LYASHENKO (Kiev, Ukraine)
08:30P1033Recurrent heart failure-related hospitalizations in patients with mid-range ejection fractionJose LUPON (Badalona, Spain)
08:30P1034Androgen status in non-diabetic elderly men with heart failureGoran LONCAR (Belgrade, Serbia)
08:30P1035Clinical characteristics and management of hospitalized patients with heart failure, results from Mongolia Ganchimeg ULZIISAIKHAN (Ulaanbaatar, Mongolia)
08:30P1036Ambulatory blood pressure monitoring in heart failure with preserved ejection fraction patientsVitalina YAROSH (Kyiv, Ukraine)
08:30P1037A comparison of non-invasive methods of measuring body composition in patients with heart failure, a report from SICA-HF.Vennela BOYALLA (London, United Kingdom)
08:30P1038The quality of life and level of depression of patients with heart failure and comorbid diabetes mellitus type 2Valentyn MASLOVSKYI (Vinnytsya, Ukraine)
08:30P1039Duration of heart failure, hospitalization rate and treatment compliance in elderly heart failure patients with anemia of chronic diseases.Dmitry SHCHEKOCHIKHIN (Moscow, Russian Federation)
08:30P1041Global analysis of survival of patients of the study remadhe randomized prospective submitted to the DMP with follow-up of 16 years